...
首页> 外文期刊>Southern African Journal of Epidemiology and Infection >Efficacy of antimicrobial lock solutions in preventing catheter-related blood stream infection in haemodialysis patients: a systematic review and meta-analysis of prospective randomised controlled trials
【24h】

Efficacy of antimicrobial lock solutions in preventing catheter-related blood stream infection in haemodialysis patients: a systematic review and meta-analysis of prospective randomised controlled trials

机译:抗菌锁溶液预防血液透析患者导管相关血流感染的功效:前瞻性随机对照试验的系统评价和荟萃分析

获取原文
           

摘要

Background: Catheter-related blood stream infection (CRBSI) contributes to morbidity and mortality among patients on haemodialysis (HD). We carried out a systematic review and meta-analysis to assess the efficacy of antimicrobial lock solutions (ALS) in preventing CRBSI. Method: Electronic search of randomised controlled trials (RCTs) comparing ALS with other agents was performed up to January 2013. DerSimonian and Laird meta-analysis was performed to obtain pooled relative risk (RR) from which efficacy of ALS and numbers needed to treat (NNT) were calculated. In a restricted analysis, pooled RRs where compared using a test of interaction to calculate ratio of relative risks (RRR). Meta-regression analysis was employed to explore sources of heterogeneity. Results: Sixteen RCTs involving 2016 individuals met the inclusion criteria. The efficacy of ALS in preventing CRBSI was 80% with NNT of 3 patients to prevent one CRBSI. The RR of CRBSI was significantly lower with ALS compared with heparin-only lock solution [RR {95% confidence interval (CI)} = 0.20 (0.13-0.31)]. With low dose (≤ 5 mg/ml) and high dose (40 mg/ml) gentamicin-containing ALS, the RR (95% CI) of developing CRBSI was 0.03 (0.01-0.13) and 0.18 (0.03-0.98), respectively, with no significant difference [RRR (95% CI) = 0.2 (0.02-1.61), p = 0.126]. Heterogeneity was explained by a statistically significant association between rate of CRBSI and catheter days ( p = 0.037). Conclusion: ALS are effective in preventing CRBSI. Low dose gentamicin should be preferred over high dose gentamicin as an ALS because it offers similar benefit in preventing CRBSI with lesser risk of toxicity from systemic leakage and subsequent development of drug resistance. (Full text available online at www.medpharm.tandfonline.com/ojid ) South Afr J Infect Dis 2016; DOI: 10.1080/23120053.2016.1156811
机译:背景:在血液透析(HD)患者中,与导管相关的血流感染(CRBSI)会增加患者的发病率和死亡率。我们进行了系统的审查和荟萃分析,以评估抗菌素锁定溶液(ALS)预防CRBSI的功效。方法:截至2013年1月,进行了将ALS与其他药物进行比较的随机对照试验(RCT)的电子搜索。进行了DerSimonian和Laird荟萃分析,以收集汇总相对风险(RR),从中可以比较ALS的疗效和治疗所需的数字( NNT)。在受限分析中,使用交互作用测试比较合并的RR,以计算相对风险比率(RRR)。使用元回归分析来探索异质性的来源。结果:涉及2016年个人的16项RCT符合纳入标准。 ALS预防CRBSI的疗效为80%,其中3例患者的NNT预防1例CRBSI。与仅使用肝素的锁定溶液相比,使用ALS的CRBSI的RR显着降低[RR {95%置信区间(CI)} = 0.20(0.13-0.31)]。在低剂量(≤5 mg / ml)和高剂量(40 mg / ml)的含庆大霉素的ALS中,发育中的CRBSI的RR(95%CI)分别为0.03(0.01-0.13)和0.18(0.03-0.98)。 ,无显着差异[RRR(95%CI)= 0.2(0.02-1.61),p = 0.126]。异质性可以通过CRBSI发生率与导管天数之间的统计学显着关联来解释(p = 0.037)。结论:ALS可有效预防CRBSI。低剂量庆大霉素应优先于高剂量庆大霉素作为ALS,因为它在预防CRBSI方面具有相似的益处,并且具有较低的全身性泄漏毒性和随后的耐药性风险。 (全文可在线访问,网址为www.medpharm.tandfonline.com/ojid)South Afr J Infect Dis 2016; DOI:10.1080 / 23120053.2016.1156811

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号